Tailored Smoking Cessation Therapy for Smoking Addiction
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.
Who Is on the Research Team?
Hilary Tindle, MD, MPH
Principal Investigator
Vanderbilt University Medical Center
Are You a Good Fit for This Trial?
This trial is for daily smokers over 18 with a regular healthcare provider, who are willing to try quitting smoking after hospital discharge. They must be able to use nicotine replacement or varenicline, have phone access, a permanent address, and prescription coverage. Those too ill, in hospice care, not cognitively able to participate or already in another smoking study can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either MIST or Usual Care interventions, with medication prescriptions tailored or not tailored to nicotine metabolism
Follow-up
Participants are monitored for abstinence and clinical practice implementation at 6 and 12 months
What Are the Treatments Tested in This Trial?
Interventions
- Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)
- Nicotine Replacement Therapy
- Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach
- Varenicline
Nicotine Replacement Therapy is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt-Ingram Cancer Center
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Cancer Institute (NCI)
Collaborator